Abstract
BackgroundControl of the global Tuberculosis (TB) burden is hindered by the lack of a simple and effective diagnostic test that can be utilized in resource-limited settings.MethodsWe evaluated the performance of Truenat MTB™, a chip-based nucleic acid amplification test in the detection of Mycobacterium tuberculosis (MTB) in clinical sputum specimens from 226 patients with suspected pulmonary tuberculosis (TB). The test involved sputum processing using Trueprep-MAG™ (nanoparticle-based protocol run on a battery-operated device) and real-time PCR performed on the Truelab Uno™ analyzer (handheld, battery-operated thermal cycler). Specimens were also examined for presence of MTB using smear microscopy, liquid culture and an in-house nested PCR protocol. Results were assessed in comparison to a composite reference standard (CRS) consisting of smear and culture results, clinical treatment and follow-up, and radiology findings.ResultsBased on the CRS, 191 patients had “Clinical-TB” (Definite and Probable-TB). Of which 154 patients are already on treatment, and 37 were treatment naïve cases. Remaining 35 were confirmed “Non-TB” cases which are treatment naïve cases. The Truenat MTB test was found to have sensitivity and specificity of 91.1% (CI: 86.1–94.7) and 100% (CI: 90.0–100) respectively, in comparison to 90.58% (CI: 85.5–94.3) and 91.43% (CI: 76.9–98.2) respectively for the in-house nested PCR protocol.ConclusionThis preliminary study shows that the Truenat MTB test allows detection of TB in approximately one hour and can be utilized in near-care settings to provide quick and accurate diagnosis.
Highlights
Tuberculosis (TB) causes the highest number of deaths globally, attributable to a curable infectious agent [1], despite the availability of potent anti-TB medication
Performing a culture can take weeks because of the slow growth rate of TB bacilli. Molecular tests such as polymerase chain reaction (PCR), which are considerably faster than culture, often have a high turnaround time as specimens are often sent to distant laboratories
Settings Sample collection, Smear Microscopy, MGIT culture and nested PCR was performed at Hinduja Hospital and Medical Research Centre, Mumbai
Summary
Tuberculosis (TB) causes the highest number of deaths globally, attributable to a curable infectious agent [1], despite the availability of potent anti-TB medication. Reduction in TBrelated morbidity and mortality is impeded by the lack of rapid and cost-effective diagnostic tests that are implementable in resource-limited settings. Performing a culture can take weeks because of the slow growth rate of TB bacilli. Molecular tests such as polymerase chain reaction (PCR), which are considerably faster than culture, often have a high turnaround time as specimens are often sent to distant laboratories. High risk of transmission of TB makes cost-effective and rapid detection crucial to control the spread of infection. Control of the global Tuberculosis (TB) burden is hindered by the lack of a simple and effective diagnostic test that can be utilized in resource-limited settings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
